Anlon Healthcare, a Rajkot-based manufacturer of high-purity APIs and pharmaceutical intermediates, is tapping the capital markets with its IPO. While smaller in scale compared to its listed peers, the company’s financial and operational metrics provide meaningful insights when benchmarked against similar players in the Indian specialty chemicals and API space. For Anlon Healthcare peer comparison, Kronox Lab Sciences, Acutaas Chemicals (AMI Organics), and Supriya Lifesciences have been considered — each operating in segments overlapping with Anlon’s portfolio.
Peer benchmarking is essential here, as it not only highlights where Anlon stands today but also signals its potential positioning post-expansion.
2. Anlon Healthcare vs Peers: Valuation Comparison
| Metric | Anlon Healthcare | Kronox Lab Sciences | Acutaas Chemicals (AMI) | Supriya Lifesciences |
|---|---|---|---|---|
| EPS (INR) | 6.38 | 6.90 | 23.1 | 22.1 |
| P/E (x) | 22.3–23.6 | 24.7 | 61.3 | 30.8 |
| P/B (x) | 4.51 | 6.99 | 8.86 | 5.46 |
| P/S (x) | 4.02 | 6.35 | 11.2 | 8.06 |
| Current Ratio | 2.64 | 7.28 | 3.91 | 5.32 |
| ROE (%) | 25.5 | 32.6 | 16.0 | 20.7 |
| ROCE (%) | 21.9 | 43.8 | 19.9 | 27.4 |
| Debt/Equity | 0.73 | 0.00 | 0.40 | 0.01 |
Deeper Insights:
- Valuation Multiples: Anlon’s P/E band (22.3–23.6x) is very close to Kronox (24.7x) — both companies are mid-scale players with comparable earnings profiles. However, Acutaas trades at a steep 61x multiple, reflecting its size and stronger institutional interest, while Supriya is at ~31x. The relative discount positions Anlon as a rationally priced emerging player.
- Price to Sales (P/S): At 4.02x, Anlon looks attractive compared to Supriya (8.1x) and Acutaas (11.2x). This shows that investors are paying far less for each unit of revenue generated by Anlon, suggesting upside potential if growth sustains.
- Price to Book (P/B): Anlon’s 4.5x is at a discount to peers like Kronox (7.0x) and Acutaas (8.9x). This indicates a relatively cheaper valuation relative to net assets, particularly important for companies with strong return metrics.
- Liquidity Strength (Current Ratio): Anlon’s Current Ratio (2.6) is lower than peers (5–7), reflecting a tighter working capital cycle. This can be read both ways: (a) peers enjoy higher liquidity cushions, but (b) Anlon is more efficient in deploying working capital without compromising solvency.
- Return Ratios: With ROE at 25.5% and ROCE at 21.9%, Anlon demonstrates strong efficiency — better than Acutaas (ROE 16%) and on par with Supriya. Kronox is an outlier with extraordinary ratios (ROE 32.6%, ROCE 43.8%), but Anlon’s performance is robust for its scale.
- Debt Profile: With a Debt/Equity ratio of 0.73, Anlon carries higher leverage than peers like Supriya (0.01) and Kronox (virtually debt-free). However, this is a vast improvement from its earlier debt levels (FY23: 9.0x), showing aggressive deleveraging through internal accruals and IPO proceeds.
3. Peer Group Positioning
When placed side by side, the peer set offers a clear perspective on how Anlon Healthcare fits into the broader specialty chemicals and API landscape:
- Kronox Lab Sciences – A close comparable in terms of revenue scale (INR 100 Cr vs Anlon’s INR 120 Cr). Kronox trades at a P/E of ~25x, slightly above Anlon. Its return ratios (ROE 32.6%, ROCE 43.8%) are superior, but Anlon is not far behind with ROE 25.5% and ROCE 21.9%. This positions Anlon as a credible mid-tier player at valuations aligned with Kronox.
- Acutaas Chemicals (AMI Organics) – Significantly larger with revenues of over INR 1,007 Cr, Acutaas commands a premium valuation (P/E ~61x, P/S ~11x). However, its profitability margins and return ratios (ROE 16%, ROCE 19.9%) lag behind Anlon. This suggests that while Acutaas benefits from scale, Anlon offers superior efficiency and returns at a fraction of the valuation multiple.
- Supriya Lifesciences – A mid-to-large scale player with revenues of ~INR 696 Cr, Supriya trades at a P/E of ~31x and P/S of 8.1x. Its EBITDA and PAT margins (37%) are higher than Anlon’s, but return ratios (ROE 20.7%, ROCE 27.4%) are broadly comparable. Supriya represents the next level of scale Anlon could aspire to, but Anlon’s relative valuations make it more accessible at this stage.
Positioning Summary: Anlon sits between Kronox and Supriya in terms of scale, with efficiency and profitability that rival or exceed larger peers. It does not yet command the premium multiples of Supriya or Acutaas, but this also leaves valuation headroom as the company scales up.
4. Anlon Healthcare vs Peers: Valuation Outlook
From Anlon Healthcare peer comparison standpoint, the company’s IPO pricing offers a reasonable entry point:
- Earnings Multiple (P/E): At ~23x, Anlon is priced in line with Kronox but at a meaningful discount to Supriya (31x) and Acutaas (61x). This suggests the IPO is not aggressively priced, leaving room for future re-rating.
- Sales & Book Value Multiples (P/S & P/B):
- P/S of 4.0x vs peers at 6–11x indicates investors are paying less for each unit of revenue.
- P/B of 4.5x also places it below Kronox and Acutaas, offering a cushion relative to asset-backed value.
- Returns (ROE/ROCE): Among the strongest in the set, reinforcing that even at a smaller scale, Anlon is generating efficient returns.
- Forward Triggers:
- Capacity Expansion – The new 700 MTPA plant will take capacity to 1,100 MTPA, more than doubling potential output. Execution here will be a key driver for scaling revenues closer to Supriya’s levels.
- Export Diversification – Currently just 3% of revenues, but with 21 DMF filings across regulated markets, exports can meaningfully alter revenue mix.
- Custom Manufacturing (CRAMS model) – Though not yet monetised, this high-margin stream could mirror success stories of larger peers and act as a structural re-rating trigger.
- Industry Tailwinds – The China+1 strategy, rising global demand for APIs, and government support to domestic pharma intermediates will likely expand market opportunities.
Conclusion
A peer-focused lens highlights Anlon Healthcare’s strengths and constraints clearly:
- Strengths:
- Valuations are rational compared to premium peers.
- Strong ROE (25.5%) and ROCE (21.9%), among the best in class.
- Margins are competitive, outperforming even large-scale peer Acutaas.
- Debt has been significantly reduced, improving financial resilience.
- Constraints:
- Revenue base is still modest (INR 120 Cr vs peers at INR 500–700 Cr+).
- Current ratio is lower than peers, reflecting tighter liquidity buffers.
- Export revenues are yet to scale meaningfully despite regulatory approvals.
In the broader peer landscape, Anlon Healthcare stands out as a nimble, high-return player trading at reasonable valuations. While its scale is smaller, its efficiency metrics and profitability profile already compare favorably with larger peers. If expansion and export execution materialise as planned, Anlon could bridge the gap with mid-cap peers like Supriya and eventually position itself closer to larger names like Acutaas.
For investors, this sets up an opportunity to participate in an emerging growth story that is competitively valued within its peer group.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.